These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1295 related articles for article (PubMed ID: 7911399)

  • 1. Progress with proton pump inhibitors in acid peptic disease: treatment of duodenal and gastric ulcer.
    Florent C
    Clin Ther; 1993; 15 Suppl B():14-21. PubMed ID: 7911399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Duodenal ulcer and gastroesophageal reflux disease today: long-term therapy--a sideways glance.
    Bardhan KD
    Yale J Biol Med; 1996; 69(3):211-24. PubMed ID: 9165690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lansoprazole: a comprehensive review.
    Zimmermann AE; Katona BG
    Pharmacotherapy; 1997; 17(2):308-26. PubMed ID: 9085323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Lansoprazole--profile of a new proton pump inhibitor].
    Seifert E
    Leber Magen Darm; 1994 Mar; 24(2):66-8, 71. PubMed ID: 8196467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical evaluation of lansoprazole in the treatment of peptic ulcers: initial healing and prevention of relapse. Tohoku Peptic Ulcer Study Group.
    Asaki S; Sato A; Sakurada H; Takeda T; Hongo M; Toyota T
    J Clin Gastroenterol; 1995; 20 Suppl 2():S56-8. PubMed ID: 7594342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. pH, healing rate, and symptom relief in patients with GERD.
    Huang JQ; Hunt RH
    Yale J Biol Med; 1999; 72(2-3):181-94. PubMed ID: 10780580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.
    Lai KC; Chu KM; Hui WM; Wong BC; Hu WH; Wong WM; Chan AO; Wong J; Lam SK
    Am J Med; 2005 Nov; 118(11):1271-8. PubMed ID: 16271912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological and pharmacodynamic essentials of H(2)-receptor antagonists and proton pump inhibitors for the practising physician.
    Huang JQ; Hunt RH
    Best Pract Res Clin Gastroenterol; 2001 Jun; 15(3):355-70. PubMed ID: 11403532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lansoprazole and Helicobacter pylori infection.
    Pallone F; Luzza F; Delle Fave G; Annibale B; Marcheggiano A; Biancone L; Torsoli A; Capurso L
    Clin Ther; 1993; 15 Suppl B():49-57. PubMed ID: 8205595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [H2 receptor antagonists and proton pump inhibitors: principles and rules of use].
    Bardou M
    Rev Prat; 2001 Apr; 51(7):789-95. PubMed ID: 11387678
    [No Abstract]   [Full Text] [Related]  

  • 11. Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer.
    Poynard T; Lemaire M; Agostini H
    Eur J Gastroenterol Hepatol; 1995 Jul; 7(7):661-5. PubMed ID: 8590162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of gastroesophageal (acid) reflux with lansoprazole: an overview.
    Dobrilla G; Di Fede F
    Clin Ther; 1993; 15 Suppl B():2-13. PubMed ID: 7911400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Comparative effect of lansoprazole/amoxicillin with omeprazole/amoxicillin for the eradication of Helicobacter pylori in patients with duodenal ulcer].
    Kayser S; Flury R; Zbinden R; Fried M; Wirth HP
    Schweiz Med Wochenschr; 1997 Apr; 127(17):722-7. PubMed ID: 9221483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Double-blind controlled-clinical trials of lansoprazole in the treatment of peptic ulcer].
    Ogawa N
    Nihon Rinsho; 1992 Jan; 50(1):68-73. PubMed ID: 1347332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effectiveness and safety of lansoprazole in the treatment of peptic ulcer].
    Ramón Nogueira J; Esquivel Ayanegui F; Esquivel Rodríguez F; Sáenz V; Santoyo R
    Rev Gastroenterol Mex; 1996; 61(4):314-9. PubMed ID: 9072782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can lansoprazole, amoxicillin, and clarithromycin combination still be used as a first-line therapy for eradication of helicobacter pylori?
    Güliter S; Keleş H; Ozkurt ZN; Cengiz DU; Kolukisa E
    Turk J Gastroenterol; 2005 Mar; 16(1):29-33. PubMed ID: 16252185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Are proton pump inhibitors superior to H2 receptor antagonists within the scope of H. pylori eradication therapy? Meta analysis of current parallel group comparisons].
    Holtmann G; Layer P; Goebell H
    Z Gastroenterol; 1996 May; 34(5):267-72. PubMed ID: 8686357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-steroidal anti-inflammatory drug gastropathy: clinical results with H2 antagonists and proton pump inhibitors.
    Lazzaroni M; Bianchi Porro G
    Ital J Gastroenterol Hepatol; 1999; 31 Suppl 1():S73-8. PubMed ID: 10379473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triple versus dual therapy for eradicating Helicobacter pylori and preventing ulcer recurrence: a randomized, double-blind, multicenter study of lansoprazole, clarithromycin, and/or amoxicillin in different dosing regimens.
    Schwartz H; Krause R; Sahba B; Haber M; Weissfeld A; Rose P; Siepman N; Freston J
    Am J Gastroenterol; 1998 Apr; 93(4):584-90. PubMed ID: 9576452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Double-blind comparison of lansoprazole, ranitidine, and placebo in the treatment of acute duodenal ulcer. Lansoprazole Study Group.
    Lanza F; Goff J; Scowcroft C; Jennings D; Greski-Rose P
    Am J Gastroenterol; 1994 Aug; 89(8):1191-200. PubMed ID: 8053433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 65.